Home Newsfeeds Roth Capital Downgrades Evolution Petroleum to Neutral

Roth Capital Downgrades Evolution Petroleum to Neutral

Roth Capital analyst John White downgrades Evolution Petroleum (AMEX:EPM) from Buy to Neutral.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Roth Capital analyst John White downgrades Evolution Petroleum (AMEX:EPM) from Buy to Neutral.

News

Airbnb Says ‘Countries with an increase in inflation saw an increase in the number of new Airbnb Hosts in Q2 2022.’

By Benzinga Newsdesk

August 10, 8:10 AM

https://news.airbnb.com/while-inflation-in-the-us-rises-new-hosts-grow-in-q2-2022/

ABNB

Dogecoin Daily: Crypto Reacts To Record Inflation Numbers, Co-Creator Recommends Reading Karl Marx

By Shivdeep Dhaliwal

July 14, 9:35 AM

Dogecoin (CRYPTO: DOGE) traded nearly flat at $0.06 over 24 hours leading up to early Thursday morning. DOGE saw minimal movement while other major coins traded slightly in the green at press time. The global cryptocurrency market cap registered a 2.4% increase to $892.7 billion.

$DOGE

HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $12

By Benzinga Newsdesk

March 20, 4:29 AM

HC Wainwright & Co. analyst Ed Arce maintains CymaBay Therapeutics (NASDAQ:CBAY) with a Buy and raises the price target from $10 to $12.

CBAY

News

Genmab and Seagen Announced That TIVDAK Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

By Charles Gross

September 4, 3:57 PM

Genmab A/S (NASDAQ:GMAB) and Seagen Inc. (NASDAQ:SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or

GMAB

Roth Capital Downgrades Evolution Petroleum to Neutral

Related Posts

Airbnb Says ‘Countries with an increase in inflation saw an increase in the number of new Airbnb Hosts in Q2 2022.’

Dogecoin Daily: Crypto Reacts To Record Inflation Numbers, Co-Creator Recommends Reading Karl Marx

HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $12

Genmab and Seagen Announced That TIVDAK Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy